Luke Miels, GSK chief commercial officer

GSK read­ies Blenrep's com­mer­cial re-launch in the US, and a push in sec­ond line

GSK is gear­ing up for the re­vival of mul­ti­ple myelo­ma drug Blenrep, hav­ing hung on­to the sales­force that was as­sem­bled when the drug first nabbed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.